CYP2C19

Across TCGA pan-cancer cohorts, CYP2C19 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2C19 data layer compared with 16 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CYP2C19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP2C19 expression acts as an unfavorable survival marker.

LUAD, LGG, and KIRC are the cancer types where CYP2C19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.340	0.689	<.001	24	view →
LGG	OS	Median	All	0.272	0.812	<.001	15	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.009	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP2C19–LUAD (OS)

Open the LUAD breakdown →